JP2020522281A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522281A5 JP2020522281A5 JP2020518573A JP2020518573A JP2020522281A5 JP 2020522281 A5 JP2020522281 A5 JP 2020522281A5 JP 2020518573 A JP2020518573 A JP 2020518573A JP 2020518573 A JP2020518573 A JP 2020518573A JP 2020522281 A5 JP2020522281 A5 JP 2020522281A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- sequence
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 27
- 239000000427 antigen Substances 0.000 claims 25
- 108091007433 antigens Proteins 0.000 claims 25
- 102000036639 antigens Human genes 0.000 claims 25
- 238000000034 method Methods 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 4
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 206010039509 Scab Diseases 0.000 claims 1
- 230000009824 affinity maturation Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (25)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762517149P | 2017-06-08 | 2017-06-08 | |
| US201762517150P | 2017-06-08 | 2017-06-08 | |
| US62/517,150 | 2017-06-08 | ||
| US62/517,149 | 2017-06-08 | ||
| US201762517753P | 2017-06-09 | 2017-06-09 | |
| US201762517745P | 2017-06-09 | 2017-06-09 | |
| US201762517734P | 2017-06-09 | 2017-06-09 | |
| US201762517740P | 2017-06-09 | 2017-06-09 | |
| US201762517164P | 2017-06-09 | 2017-06-09 | |
| US201762517165P | 2017-06-09 | 2017-06-09 | |
| US62/517,164 | 2017-06-09 | ||
| US62/517,165 | 2017-06-09 | ||
| US62/517,753 | 2017-06-09 | ||
| US62/517,745 | 2017-06-09 | ||
| US62/517,740 | 2017-06-09 | ||
| US62/517,734 | 2017-06-09 | ||
| US201762582681P | 2017-11-07 | 2017-11-07 | |
| US201762582666P | 2017-11-07 | 2017-11-07 | |
| US201762582676P | 2017-11-07 | 2017-11-07 | |
| US201762582653P | 2017-11-07 | 2017-11-07 | |
| US62/582,653 | 2017-11-07 | ||
| US62/582,666 | 2017-11-07 | ||
| US62/582,676 | 2017-11-07 | ||
| US62/582,681 | 2017-11-07 | ||
| PCT/EP2018/065243 WO2018224685A1 (en) | 2017-06-08 | 2018-06-08 | Cd38 modulating antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020522281A JP2020522281A (ja) | 2020-07-30 |
| JP2020522281A5 true JP2020522281A5 (show.php) | 2021-07-26 |
| JP7237951B2 JP7237951B2 (ja) | 2023-03-13 |
Family
ID=62620847
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020518573A Active JP7237951B2 (ja) | 2017-06-08 | 2018-06-08 | Ｃｄ３８調節抗体 |
| JP2020518572A Active JP7237950B2 (ja) | 2017-06-08 | 2018-06-08 | Ｃｄ３８調節抗体 |
| JP2022202855A Active JP7467584B2 (ja) | 2017-06-08 | 2022-12-20 | Ｃｄ３８調節抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020518572A Active JP7237950B2 (ja) | 2017-06-08 | 2018-06-08 | Ｃｄ３８調節抗体 |
| JP2022202855A Active JP7467584B2 (ja) | 2017-06-08 | 2022-12-20 | Ｃｄ３８調節抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US12343394B2 (show.php) |
| EP (2) | EP3635002A1 (show.php) |
| JP (3) | JP7237951B2 (show.php) |
| KR (3) | KR20250025514A (show.php) |
| CN (2) | CN110997723B (show.php) |
| AU (3) | AU2018280871B2 (show.php) |
| CA (2) | CA3066553A1 (show.php) |
| WO (2) | WO2018224685A1 (show.php) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250025514A (ko) | 2017-06-08 | 2025-02-21 | 블랙 벨트 테라퓨틱스 리미티드 | Cd38 조정 항체 |
| EP3668896A1 (en) | 2017-08-16 | 2020-06-24 | Black Belt Therapeutics Limited | Cd38 modulating antibody |
| CN110144008B (zh) * | 2018-02-12 | 2021-03-19 | 杭州尚健生物技术有限公司 | Cd38蛋白抗体及其应用 |
| SG11202106963YA (en) | 2019-01-11 | 2021-07-29 | Omeros Corp | Methods and compositions for treating cancer |
| WO2020152290A1 (en) * | 2019-01-23 | 2020-07-30 | Encefa | Cd31 competitors and uses thereof |
| US12453738B2 (en) | 2019-03-12 | 2025-10-28 | Arcus Biosciences, Inc. | Treatment of oncogene-driven cancers |
| EP3947463A4 (en) | 2019-03-29 | 2022-12-21 | Arcus Biosciences, Inc. | TREATMENT OF CANCER USING AN IDENTIFIED ADENOSINE FINGERPRINT |
| CN114524877A (zh) * | 2019-03-29 | 2022-05-24 | 索伦托药业有限公司 | 结合cd38的经工程改造的变异抗体 |
| TW202227493A (zh) | 2020-09-10 | 2022-07-16 | 美商英創遠達製藥公司 | 血液篩選之方法 |
| CN114457028A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达cd38抗体的多能干细胞及其衍生物与应用 |
| CN114437215B (zh) * | 2020-11-05 | 2023-02-07 | 上海麦济生物技术有限公司 | 抗人cd38抗体及其制备方法和用途 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) * | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| US20030148321A1 (en) * | 2001-08-24 | 2003-08-07 | Iris Pecker | Methods and kits for diagnosing and monitoring hematopoietic cancers |
| AU2011202520C1 (en) * | 2002-10-17 | 2016-02-18 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US8039218B2 (en) * | 2002-11-14 | 2011-10-18 | John Wayne Cancer Institute | Detection of cancer cells in body fluids |
| NZ548990A (en) | 2004-02-06 | 2009-06-26 | Morphosys Ag | Anti-CD38 human antibodies and uses therefor |
| US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| AU2005235811B2 (en) | 2004-02-06 | 2011-11-03 | Morphosys Ag | Anti-CD38 human antibodies and uses therefor |
| NZ561883A (en) * | 2005-03-23 | 2010-11-26 | Genmab As | Antibodies against CD38 for treatment of multiple myeloma |
| EP1872124A4 (en) * | 2005-04-19 | 2008-06-11 | Prediction Sciences Llc | DIAGNOSIS MARKET FOR BREAST CANCER TREATMENT AND PROGRESSION AND METHOD OF USE THEREOF |
| US20090123950A1 (en) | 2005-05-24 | 2009-05-14 | Morphosys Ag | Generation And Profiling Of Fully Human Hucal Gold®-Derived Therapeutic Antibodies Specific For Human CD38 |
| KR101512853B1 (ko) | 2005-10-12 | 2015-04-28 | 모르포시스 아게 | 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링 |
| AU2016228249A1 (en) * | 2006-09-26 | 2016-10-06 | Genmab A/S | Combination treatment of CD38-expressing tumors |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| AU2013209322A1 (en) | 2006-10-19 | 2013-08-15 | Sanofi-Aventis | Novel anti-cd38 antibodies for the treatment of cancer |
| KR101552735B1 (ko) | 2006-12-01 | 2015-09-14 | 메다렉스, 엘.엘.시. | 씨디22에 결합하는 인간 항체 및 이의 용도 |
| CN101605906A (zh) | 2006-12-14 | 2009-12-16 | 梅达雷克斯公司 | 结合cd70的人类抗体及其用途 |
| CA2672468A1 (en) | 2006-12-14 | 2008-06-19 | Medarex, Inc. | Human antibodies that bind cd70 and uses thereof |
| NZ600281A (en) | 2006-12-27 | 2013-03-28 | Harvard College | Compositions and methods for the treatment of infections and tumors |
| WO2009036379A2 (en) | 2007-09-14 | 2009-03-19 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| DK2342220T3 (da) | 2008-10-06 | 2021-08-09 | Univ British Columbia | Metoder og systemer til forudsigelse af misfoldede proteinepitoper |
| US8642292B2 (en) | 2009-09-22 | 2014-02-04 | Probiogen Ag | Process for producing molecules containing specialized glycan structures |
| WO2011035433A1 (en) * | 2009-09-23 | 2011-03-31 | University Health Network | Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers |
| CN105734678B (zh) | 2010-07-16 | 2019-11-05 | 阿迪马布有限责任公司 | 合成多核苷酸文库 |
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| GB201300346D0 (en) * | 2013-01-09 | 2013-02-20 | Biolnvent Internat Ab | BiologIcal materials and uses thereof |
| GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| AR095517A1 (es) | 2013-03-15 | 2015-10-21 | Genentech Inc | ANTICUERPOS CONTRA EL RECEPTOR QUIMIOATRAYENTE EXPRESADO EN CÉLULAS T HELPER 2 (ANTI-CRTh2) Y MÉTODOS DE USO |
| EP3104882B1 (en) | 2014-02-14 | 2019-06-05 | Centrose, Llc | Extracellular targeted drug conjugates |
| EA201691925A1 (ru) | 2014-03-28 | 2017-06-30 | Ксенкор, Инк. | Биспецифические антитела, которые связываются с cd38 и cd3 |
| MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| MX2017007187A (es) | 2014-12-01 | 2018-01-30 | Univ Pennsylvania | Construcciones de anticuerpos de adn y metodo para utilizarlas. |
| US10059774B2 (en) | 2015-04-08 | 2018-08-28 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CD38 |
| GB201506389D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| US20160376373A1 (en) | 2015-06-24 | 2016-12-29 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| EP3356415B1 (en) | 2015-09-29 | 2024-05-01 | Amgen Inc. | Asgr inhibitors for reduzing cholesterol levels |
| CN115746143A (zh) | 2015-10-02 | 2023-03-07 | 豪夫迈·罗氏有限公司 | 对共刺激性tnf受体特异性的双特异性抗体 |
| KR20250025514A (ko) | 2017-06-08 | 2025-02-21 | 블랙 벨트 테라퓨틱스 리미티드 | Cd38 조정 항체 |
| WO2021057978A1 (zh) * | 2019-09-27 | 2021-04-01 | 南京金斯瑞生物科技有限公司 | 抗vhh域抗体及其用途 |
-
2018
- 2018-06-08 KR KR1020257004706A patent/KR20250025514A/ko active Pending
- 2018-06-08 KR KR1020207000253A patent/KR102719065B1/ko active Active
- 2018-06-08 US US16/620,589 patent/US12343394B2/en active Active
- 2018-06-08 WO PCT/EP2018/065243 patent/WO2018224685A1/en not_active Ceased
- 2018-06-08 CN CN201880049994.2A patent/CN110997723B/zh active Active
- 2018-06-08 EP EP18731394.5A patent/EP3635002A1/en active Pending
- 2018-06-08 CA CA3066553A patent/CA3066553A1/en active Pending
- 2018-06-08 EP EP18731395.2A patent/EP3635003A1/en active Pending
- 2018-06-08 US US16/621,314 patent/US12161717B2/en active Active
- 2018-06-08 KR KR1020207000247A patent/KR102770106B1/ko active Active
- 2018-06-08 JP JP2020518573A patent/JP7237951B2/ja active Active
- 2018-06-08 WO PCT/EP2018/065239 patent/WO2018224683A1/en not_active Ceased
- 2018-06-08 JP JP2020518572A patent/JP7237950B2/ja active Active
- 2018-06-08 CA CA3066555A patent/CA3066555A1/en active Pending
- 2018-06-08 AU AU2018280871A patent/AU2018280871B2/en active Active
- 2018-06-08 AU AU2018280869A patent/AU2018280869B2/en active Active
- 2018-06-08 CN CN201880049993.8A patent/CN110997722B/zh active Active
-
2022
- 2022-12-20 JP JP2022202855A patent/JP7467584B2/ja active Active
-
2025
- 2025-03-17 AU AU2025201908A patent/AU2025201908A1/en active Pending
- 2025-05-20 US US19/213,464 patent/US20250367286A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020522281A5 (show.php) | ||
| JP2020522280A5 (show.php) | ||
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| IL276830B2 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| JPWO2019175226A5 (show.php) | ||
| JPWO2019175215A5 (show.php) | ||
| JP2020528750A5 (show.php) | ||
| JP2020533965A5 (show.php) | ||
| RU2018145852A (ru) | Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение | |
| JPWO2019175217A5 (show.php) | ||
| JPWO2019175220A5 (show.php) | ||
| JPWO2019175216A5 (show.php) | ||
| JP2018534933A5 (show.php) | ||
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| CN109843927A (zh) | 抗b7-h3抗体、其抗原结合片段及其医药用途 | |
| US20220340673A1 (en) | Antibody targeting bcma, bispecific antibody, and use thereof | |
| JPWO2019175224A5 (show.php) | ||
| JPWO2019175222A5 (show.php) | ||
| JPWO2019175223A5 (show.php) | ||
| JP2014524902A5 (show.php) | ||
| RU2019104980A (ru) | Анти-icos антитела | |
| RU2016122340A (ru) | Il-17a-связующий агент и способы его применения | |
| JP2024024114A5 (show.php) | ||
| RU2019139093A (ru) | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение | |
| JP2020531003A5 (show.php) |